Modern insulin therapy with insulin analogues detemir and aspart in children and adolescents: The problems and solutions
https://doi.org/10.14341/probl201359680-86
Abstract
DCCT (Diabetes Control and Complications Trial) study showed that intensified insulin therapy associates with significant reduction both of development and progression of vascular complications compared to conventional insulin therapy in type 1 diabetic patients. Modern algorithms of diabetes treatment in children and adolescents reflect the need to achieve and maintenance of glycemic control as closely as possible to normal level. Insulin analogues have improved pharmacokinetic and pharmacodynamic properties, and also have less variability than human insulin. So they have more physiologic and predictable profile actions and, therefore, provide the possibility to achieve optimal glycemic control with low risk of hypoglycemia. Current review demonstrates the benefits of basal-bolus therapy with insulin analogues detemir (Levemir) and aspart (NovoRapid) and advantages of insulin NovoRapid in the continuous subcutaneous insulin infusion (CSII) compared with human insulin in children and adolescents with type 1 diabetes mellitus.
References
1. Banting F.G., Best C.H. The internal secretion of pancreas. J Lab Clin Med 1922; 7: 251-266, http://www.biology.buffalo.edu/courses/bio130/medler/banting.pdf
2. Дедов И.И. История открытия инсулина. Вестн РДА 2011; 15.
3. Narayan K.M.V., Boyle J.P., Thompson T.J., Sorensen S.W., Williamson D.F. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 14: 1884-1890.
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-178.
6. White N.H., Cleary P.A., Dahms W. et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001; 139: 804-812.
7. White N.H., Sun W., Cleary P.A., Tamborlane W.V., Danis R.P., Hainsworth D.P., Davis M.D., and for the DCCT-EDIC Research Group. Effect of prior intensive therapy in Type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: Comparison of adults and adolescents. Diabetes 2010; 59: 1244-1253, doi:10.2337/db09-1216.
8. Diabetes Control and Complications Trial (DCCT) Research Group. The relationship of glycaemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983.
9. Hirsch I.B., Brownlee M. Should minimal blood glucose variability become the gold standard of glycaemic control? Diabetes Complications 2005; 19: 178-181.
10. ISPAD Clinical Practice Consensus Guidelines, 2009. Compendium. Pediatr Diabet 2009; 10: Suppl 12: 210.
11. American Diabetes Association (ADA) Standards of Medical Care in Diabetes 2006. Diabet Care 2006; 29: Suppl 1: S4-S42.
12. Дедов И.И., Петеркова В.А., Кураева Т.Л. Российский консенсус по терапии сахарного диабета у детей и подростков. Сахарный диабет 2010; 1-8 (спецвыпуск).
13. Danne T., Datz N., Endahl L. et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabet 2008; 9: 554-560.
14. Петеркова В.А., Кураева Т.Л., Андрианова Е.А., Емельянов А.О. Инсулиновые аналоги в лечении сахарного диабета 1 типа у детей и подростков. Пособие для врачей. Под ред. И.И. Дедова. М: Институт проблем управления здравоохранением 2009.
15. Hirsch I.B. Insulin analogues. N Engl J Med 2005; 352: 174-183.
16. Garg S., Moser E., Dain M.P., Rodonova A. Clinical experience with insulin glargine in Type 1 diabetes. Diabetes Technol Ther 2010; 12: 11: 835-846.
17. Danne T., Rastam J., Odendahl R., Nake A., Schimmel U., Szczepanski R., Moeller J., Deiss D. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes. Pediatr Diabet 2007; 8: 278-285.
18. Thalange N., Bereket A., Larsen J., Hiort L.C., Peterkova V. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus. Paediatr Diabet 2011; 21: 1399-5448.
19. Thalange N., Bereket A., Larsen J., Hiort L.C., Peterkova V. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial. Diabet Med 2013; 30: 216-225.
20. Scheiner G., Boyer B.F. Characteristics of basal insulin requirements by age and gender in Type 1 diabetes patients using insulin pump therapy. Diabet Res Clin Pract 2005; 69: 14-21.
21. Wilkinson J., Chase H.P., McFann K. Factors affecting improved glycemic control in youth using insulin pumps. Diabetes 2009; 58: Suppl: A 459.
22. Петеркова В.А., Кураева Т.Л., Емельянов А.О. и др. Помповая инсулинотерапия сахарного диабета у детей и подростков (Методическое пособие для педиатров-эндокринологов). М 2011.
23. Андрианова Е.А., Ширяева Т.Ю., Александрова И.И., Сунцов Ю.И. Оценка степени метаболической компенсации и распространенности диабетических осложнений в Российской популяции детей и подростков (итоги проекта "Скрининг осложнений сахарного диабета и оценка лечебной помощи больным"). Сахарный диабет 2009; 3: 37-42.
Review
For citations:
Kuraeva T.L. Modern insulin therapy with insulin analogues detemir and aspart in children and adolescents: The problems and solutions. Problems of Endocrinology. 2013;59(6):80-86. (In Russ.) https://doi.org/10.14341/probl201359680-86
Views:
479
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
